It is irritating that if true that the EMA after reviewing data in hand from the 2b/3 trial strongly encouraged an application, knowing the size of the trial, the dropout rates, its safety profile and meeting one of its primary targets and secondary ones and now feeling the data no longer is sufficient and sandbagging the company after a year of looking at the data and asking supplementary questions.
The powers that be will never let Missling win. Best hope is buyout from BP and hope they do not bury the drug. The science is too disruptive. Missling is toast.
Market Data 
Markets 
AI
